3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
11
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Sarcoma
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Lymphoma
2
Liver Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Interventions
Doxorubicin
5
pazopanib
4
Ifosfamide
3
pembrolizumab
2
Sunitinib
2
Radiotherapy, Conformal
2
Radiotherapy
2
tremelimumab
1
temsirolimus
1
sintilimab
1
saracatinib
1
sapanisertib
1
romidepsin
1
olaratumab
1
liposomal doxorubicin
1
indolepropanol phosphate
1
eribulin
1
durvalumab
1
Watchful Waiting
1
Surgical Procedures, Operative
1
Sorafenib
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Radiation
1
Polymerase Chain Reaction
1
Observation
1
Nivolumab
1
Neoadjuvant Therapy
1
Methotrexate
1
MLN 8237
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Histiocytoma, Malignant Fibrous
×
spartalizumab
×
Clear all
No trials found.